表紙
市場調査レポート

再発性多発性骨髄腫:パイプライン製品の分析

Relapsed Multiple Myeloma - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 251606
出版日 ページ情報 英文 505 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
再発性多発性骨髄腫:パイプライン製品の分析 Relapsed Multiple Myeloma - Pipeline Review, H2 2015
出版日: 2015年11月30日 ページ情報: 英文 505 Pages
概要

再発性多発性骨髄腫は、初期治療後に継続または再発します。症状には骨の痛み、貧血による脱力感および疲労、体重減少および腎臓障害などがあります。素因として年齢および家族歴が挙げられます。再発性多発性骨髄腫は、化学療法および放射線療法で管理できます。

当レポートでは、再発性多発性骨髄腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

再発性多発性骨髄腫の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

開発中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品

開発中の製品:企業別

開発中の製品:大学/研究機関別

治療薬の開発に従事している企業

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル(製品説明/作用機序/R&D進捗状況)

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6957IDB

Summary

Global Markets Direct's, 'Relapsed Multiple Myeloma - Pipeline Review, H2 2015', provides an overview of the Relapsed Multiple Myeloma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Relapsed Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Relapsed Multiple Myeloma Overview
  • Therapeutics Development
    • Pipeline Products for Relapsed Multiple Myeloma - Overview
    • Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis
  • Relapsed Multiple Myeloma - Therapeutics under Development by Companies
  • Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes
  • Relapsed Multiple Myeloma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Relapsed Multiple Myeloma - Products under Development by Companies
  • Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes
  • Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development
    • 4SC AG
    • AB Science SA
    • AbbVie Inc.
    • Acetylon Pharmaceuticals, Inc.
    • Altor BioScience Corporation
    • Amgen Inc.
    • Arno Therapeutics, Inc.
    • Array BioPharma Inc.
    • Astellas Pharma Inc.
    • Astex Pharmaceuticals, Inc.
    • Atara Biotherapeutics, Inc.
    • Biotest AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Calithera Biosciences, Inc.
    • Celgene Corporation
    • Cellectar Biosciences, Inc.
    • Cleave Biosciences
    • Curis, Inc.
    • Daiichi Sankyo Company, Limited
    • Exelixis, Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • IGF Oncology, LLC.
    • Immunomedics, Inc.
    • Jasco Pharmaceuticals, LLC.
    • Johnson & Johnson
    • JW Pharmaceutical Corporation
    • Karyopharm Therapeutics, Inc.
    • MedImmune, LLC
    • Medivation, Inc.
    • Merck & Co., Inc.
    • Millennium Pharmaceuticals, Inc.
    • MorphoSys AG
    • Novartis AG
    • Noxxon Pharma AG
    • Oncolytics Biotech Inc.
    • Oncopeptides AB
    • Onyx Pharmaceuticals, Inc.
    • Patrys Limited
    • Pfizer Inc.
    • Pharma Mar, S.A.
    • Sanofi
    • Stemline Therapeutics, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Synta Pharmaceuticals Corp.
    • Threshold Pharmaceuticals, Inc.
    • Vivolux AB
  • Relapsed Multiple Myeloma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 4SC-202 - Drug Profile
    • 765IGF-MTX - Drug Profile
    • ABBV-838 - Drug Profile
    • acalabrutinib - Drug Profile
    • ACY-241 - Drug Profile
    • afuresertib hydrochloride - Drug Profile
    • alisertib - Drug Profile
    • alpelisib - Drug Profile
    • ALT-801 - Drug Profile
    • ALT-803 - Drug Profile
    • AMG-224 - Drug Profile
    • amrubicin hydrochloride - Drug Profile
    • AR-42 - Drug Profile
    • AT-7519 - Drug Profile
    • AT-9283 - Drug Profile
    • B-701 - Drug Profile
    • bendamustine hydrochloride - Drug Profile
    • BI-836909 - Drug Profile
    • BMS-986016 - Drug Profile
    • cabozantinib s-malate - Drug Profile
    • carfilzomib - Drug Profile
    • CB-5083 - Drug Profile
    • CB-839 - Drug Profile
    • CC-90002 - Drug Profile
    • Cell Therapy to Target WT1 for Cancer - Drug Profile
    • Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma - Drug Profile
    • Cellular Immunotherapy to Target CD138 for Relapsed and Refractory Multiple Myeloma - Drug Profile
    • CUDC-907 - Drug Profile
    • CWP-291 - Drug Profile
    • daratumumab - Drug Profile
    • DKN-01 - Drug Profile
    • DS-3032 - Drug Profile
    • elotuzumab - Drug Profile
    • erismodegib - Drug Profile
    • evofosfamide - Drug Profile
    • filanesib - Drug Profile
    • ganetespib - Drug Profile
    • GSK-2857916 - Drug Profile
    • GSK-525762 - Drug Profile
    • I131-CLR1404 - Drug Profile
    • ibrutinib - Drug Profile
    • indatuximab ravtansine - Drug Profile
    • inebilizumab - Drug Profile
    • ipilimumab - Drug Profile
    • isatuximab - Drug Profile
    • ixazomib citrate - Drug Profile
    • JP-11646 - Drug Profile
    • LCL-161 - Drug Profile
    • lirilumab - Drug Profile
    • marizomib - Drug Profile
    • masitinib - Drug Profile
    • Melflufen - Drug Profile
    • milatuzumab - Drug Profile
    • MOR-202 - Drug Profile
    • MV-NIS - Drug Profile
    • NL-101 - Drug Profile
    • olaptesed pegol - Drug Profile
    • oprozomib - Drug Profile
    • palbociclib - Drug Profile
    • PATSM-6 - Drug Profile
    • pelareorep - Drug Profile
    • pembrolizumab - Drug Profile
    • pidilizumab - Drug Profile
    • PIM-447 - Drug Profile
    • plerixafor - Drug Profile
    • plitidepsin - Drug Profile
    • quisinostat hydrochloride - Drug Profile
    • Recombinant Protein for Oncology - Drug Profile
    • ricolinostat - Drug Profile
    • RRX-001 - Drug Profile
    • selinexor - Drug Profile
    • SL-401 - Drug Profile
    • trametinib dimethyl sulfoxide + uprosertib - Drug Profile
    • ulocuplumab - Drug Profile
    • urelumab - Drug Profile
    • vemurafenib - Drug Profile
    • venetoclax - Drug Profile
    • VLX-1570 - Drug Profile
    • vorinostat - Drug Profile
  • Relapsed Multiple Myeloma - Recent Pipeline Updates
  • Relapsed Multiple Myeloma - Dormant Projects
  • Relapsed Multiple Myeloma - Discontinued Products
  • Relapsed Multiple Myeloma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Relapsed Multiple Myeloma, H2 2015
  • Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by 4SC AG, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by AB Science SA, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by AbbVie Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Altor BioScience Corporation, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Amgen Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Array BioPharma Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Astellas Pharma Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Atara Biotherapeutics, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Biotest AG, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Calithera Biosciences, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Celgene Corporation, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Cellectar Biosciences, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Cleave Biosciences, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Curis, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Exelixis, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by IGF Oncology, LLC., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Immunomedics, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Johnson & Johnson, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by JW Pharmaceutical Corporation, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by MedImmune, LLC, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Medivation, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Merck & Co., Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by MorphoSys AG, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Novartis AG, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Noxxon Pharma AG, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Oncopeptides AB, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Patrys Limited, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Pfizer Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Pharma Mar, S.A., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Sanofi, H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
  • Relapsed Multiple Myeloma - Pipeline by Vivolux AB, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Relapsed Multiple Myeloma Therapeutics - Recent Pipeline Updates, H2 2015
  • Relapsed Multiple Myeloma - Dormant Projects, H2 2015
  • Relapsed Multiple Myeloma - Dormant Projects (Contd..1), H2 2015
  • Relapsed Multiple Myeloma - Dormant Projects (Contd..2), H2 2015
  • Relapsed Multiple Myeloma - Dormant Projects (Contd..3), H2 2015
  • Relapsed Multiple Myeloma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Relapsed Multiple Myeloma, H2 2015
  • Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top